Member Info for SaveShares

Getting dearer guys lets see that 2p+ obliterated before news next week i hear.

Thanks bro this is a 10p+ stock easy when the investors/retail see the light

New research using circulating tumor cells (CTCs)

https://news.cancerconnect.com/blood-tests-to-track-cancer-understanding-your-ctdna-and-liquid-biopsy-options/

Beyond ctDNA, researchers are also exploring ways to use circulating tumor cells to monitor cancer. In May 2026, CelLBxHealth announced a partnership with AdventHealth to use its Parsortix CTC platform in two large observational studies, ACTION and SUNRISE.

These studies will enroll people with colorectal, gastrointestinal, and lung cancers and will track how CTC counts and other markers change over time with chemotherapy and supportive care.

The research also pairs blood‑based monitoring with remotely delivered exercise programs, to see whether lifestyle interventions can improve treatment tolerance and possibly influence tumor biology.

CTC‑based testing is not as widely used in routine care as ctDNA today, but these trials may help clarify how CTC information could complement ctDNA and imaging in the future.

What this means for patients

For patients, the growing number of ctDNA and liquid biopsy options is both promising and confusing. Key points to keep in mind:

No test is perfect. A positive ctDNA result does not always mean the cancer will definitely come back, and a negative result does not guarantee that it will not.

Different cancers, different evidence. The amount of data supporting ctDNA testing varies by cancer type and stage. In some settings, results may already influence treatment decisions; in others, they are mainly used within clinical trials.

Choice of test matters. Tumor‑informed and blood‑only tests work differently, and your oncologist may recommend one based on your specific cancer, prior treatments, and whether tumor tissue is available.

CTC testing is emerging. CTC‑based monitoring, like the CelLBxHealth/AdventHealth studies, is still largely research‑focused but may eventually offer another layer of information alongside ctDNA.

Buyers moved in again expecting news next week had some good feedback from AdventHealth by email.

CelLBxHealth insiders may have bought shares in the last year, but they didn't sell any.

CelLBxHealth Insider Confidence Rewarded, Stock Hits UK£24m Market Cap

Last week, CelLBxHealth plc (LON:CLBX) insiders, who had purchased shares in the previous 12 months were rewarded handsomely. The shares increased by 23% last week, resulting in a UK£4.5m increase in the company's market worth, implying a 115% gain on their initial purchase. In other words, the original UK£125.0k purchase is now worth UK£268.8k.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.

CelLBxHealth Insider Transactions Over The Last Year

The Executive Chairman Jan Groen made the biggest insider purchase in the last 12 months. That single transaction was for UK£50k worth of shares at a price of UK£0.01 each. Even though the purchase was made at a significantly lower price than the recent price (UK£0.021), we still think insider buying is a positive.

Buyers starting to come in now and chunky

This is major stuff guys funded by big players

We should be 10p+ for sure and we will be on the next rns buy and sit back

2p attack looks imminent they want 2p for the last anything over 250k

They have very little to sell you looks loke big deal is done and they know it guys pushing 2p+ by close today imho

Last chance today under 2p imho

Back up through 2p shortly

Just the start

SHAREHOLDERS 🤡

Up we go wakey wakey

Yip tick up coming and plenty more .....

Pop

Go on my son

Liking this finish today going 💙💯

Broad Market Consensus

According to tracking data across aggregate platforms like London Stock Exchange ShareChat and ADVFN, analyst sentiment sits at a Strong Buy:

Conservative Average Target: 4.0p to 7.0p.

High-End Speculative Estimates: Up to 30.0p.

Valuation Forecast: Independent estimates (such as Trinity Delta) model the fundamental underlying value of the technology portfolio at up to £118 million, or roughly 37p per share, once wider commercial adoption by pharmaceutical groups is achieved.

This new partnership is huge they are a big USA player with mega funds and facilities, we will move very fast as the news starts to sink in with more news imminent for sure.